UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2008

DATASCOPE CORP.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation) 0-6516
(Commission
File Number) 13-2529596
(IRS Employer
Identification No.)

14 Philips Parkway
Montvale, New Jersey
(Address of principal executive offices) 07645-9998
(Zip Code)

(Registrant’s telephone number, including area code): (201) 391-8100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On August 7, 2008, Datascope Corp. issued a press release announcing that it has completed the sale of assets of its vascular closure business, including all assets related to its VasoSeal^®, On-Site™ and X-Site^® devices and its collagen operation, to St. Jude Medical, Inc. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information, including Exhibit 99.1, furnished in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, except as shall otherwise be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

Exhibit 99.1 Press release announcing that Datascope Corp. has completed the sale of assets of its vascular closure business to St. Jude Medical, Inc.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

DATASCOPE CORP.

Registrant
 

/s/ Henry M. Scaramelli  

     Vice President, Finance and 

     Chief Financial Officer 

     Dated: August 7, 2008

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release announcing that Datascope Corp. has completed the sale of assets of its vascular closure business to St. Jude Medical, Inc.